Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder.

Area of Science:

• Psychiatry
• Pharmacology
• Combat Veterans Mental Health

Background:

• Posttraumatic stress disorder (PTSD) is frequently associated with increased aggressive behavior.
• Combat veterans represent a population at high risk for PTSD and related symptoms like aggression and hyperarousal.

Purpose of the Study:

• To investigate the efficacy of low-dose risperidone in reducing aggression and other PTSD symptoms in male combat veterans.
• To test the hypothesis that risperidone improves hyperarousal and intrusive thoughts associated with PTSD.

Main Methods:

• A 6-week, double-blind, randomized placebo-controlled trial was conducted.
• Male combat veterans with PTSD (PCL-M cluster D score ≥20) received either risperidone (0.5-2.0 mg/day) or placebo.
• Symptom severity was assessed using the Patient Checklist for PTSD-Military Version (PCL-M) and the Overt Aggression Scale-Modified for Outpatients (OAS-M).

Main Results:

• Risperidone treatment resulted in significantly greater reductions in irritability (OAS-M) and intrusive thoughts (PCL-M cluster B) compared to placebo.
• Significant improvements were observed on the total PCL-M scale scores in the risperidone group versus placebo.
• The study demonstrated dose-dependent effects, with higher risperidone doses potentially leading to greater symptom reduction.

Conclusions:

• Low-dose risperidone is a promising therapeutic option for managing irritability and intrusive thoughts in combat-related PTSD.
• Risperidone may help mitigate aggressive behaviors and improve overall PTSD symptomology in this patient population.
• Further research is warranted to explore long-term efficacy and optimal dosing strategies for risperidone in PTSD treatment.